[go: up one dir, main page]

WO2006033912A3 - Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette - Google Patents

Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette Download PDF

Info

Publication number
WO2006033912A3
WO2006033912A3 PCT/US2005/032706 US2005032706W WO2006033912A3 WO 2006033912 A3 WO2006033912 A3 WO 2006033912A3 US 2005032706 W US2005032706 W US 2005032706W WO 2006033912 A3 WO2006033912 A3 WO 2006033912A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
bone disorders
anabolic drugs
skeletal anabolic
skeletal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/032706
Other languages
English (en)
Other versions
WO2006033912B1 (fr
WO2006033912A2 (fr
Inventor
Andrew F Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osteotrophin LLC
Original Assignee
Osteotrophin LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteotrophin LLC filed Critical Osteotrophin LLC
Priority to AU2005287139A priority Critical patent/AU2005287139A1/en
Priority to CA002580281A priority patent/CA2580281A1/fr
Priority to JP2007532415A priority patent/JP2008513459A/ja
Priority to EP05797693A priority patent/EP1799240A4/fr
Priority to MX2007003185A priority patent/MX2007003185A/es
Publication of WO2006033912A2 publication Critical patent/WO2006033912A2/fr
Publication of WO2006033912A3 publication Critical patent/WO2006033912A3/fr
Publication of WO2006033912B1 publication Critical patent/WO2006033912B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes de prévention et de traitement de diverses maladies touchant les mammifères se manifestant par une perte de la masse osseuse, telles que l'ostéoporose. L'invention concerne des méthodes utilisant PTHrP (protéine liée à l'hormone parathyroïde) ou des analogues de celles-ci, qui sont à la fois efficaces et plus sûrs, dans le traitement des affections osseuses métaboliques.
PCT/US2005/032706 2004-09-16 2005-09-14 Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette Ceased WO2006033912A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005287139A AU2005287139A1 (en) 2004-09-16 2005-09-14 Treatment of bone disorders with skeletal anabolic drugs
CA002580281A CA2580281A1 (fr) 2004-09-16 2005-09-14 Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette
JP2007532415A JP2008513459A (ja) 2004-09-16 2005-09-14 骨同化物質を用いた骨疾患の治療方法
EP05797693A EP1799240A4 (fr) 2004-09-16 2005-09-14 Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette
MX2007003185A MX2007003185A (es) 2004-09-16 2005-09-14 Tratamiento de trastornos oseos con farmacos anabolicos esqueletales.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61028304P 2004-09-16 2004-09-16
US60/610,283 2004-09-16

Publications (3)

Publication Number Publication Date
WO2006033912A2 WO2006033912A2 (fr) 2006-03-30
WO2006033912A3 true WO2006033912A3 (fr) 2006-06-29
WO2006033912B1 WO2006033912B1 (fr) 2006-09-08

Family

ID=36090476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032706 Ceased WO2006033912A2 (fr) 2004-09-16 2005-09-14 Traitement des affections osseuses a l'aide de medicaments anabolisants du squelette

Country Status (6)

Country Link
EP (1) EP1799240A4 (fr)
JP (1) JP2008513459A (fr)
AU (1) AU2005287139A1 (fr)
CA (1) CA2580281A1 (fr)
MX (1) MX2007003185A (fr)
WO (1) WO2006033912A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101661730B1 (ko) * 2007-08-01 2016-10-04 더 제너럴 하스피탈 코포레이션 Ｇ―단백질 결합 수용체를 이용한 스크리닝 방법 및 관련 조성물
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171288A1 (en) * 2002-01-10 2003-09-11 Stewart Andrew F. Treatment of bone disorders with skeletal anabolic drugs
WO2003099849A2 (fr) * 2002-05-23 2003-12-04 Michael Holick Utilisation d'analogues peptidiques d'hormone parathyroide pour le traitement de l'atrophie vaginale

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171288A1 (en) * 2002-01-10 2003-09-11 Stewart Andrew F. Treatment of bone disorders with skeletal anabolic drugs
WO2003099849A2 (fr) * 2002-05-23 2003-12-04 Michael Holick Utilisation d'analogues peptidiques d'hormone parathyroide pour le traitement de l'atrophie vaginale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1799240A4 *

Also Published As

Publication number Publication date
JP2008513459A (ja) 2008-05-01
MX2007003185A (es) 2007-10-16
EP1799240A4 (fr) 2009-07-22
AU2005287139A1 (en) 2006-03-30
WO2006033912B1 (fr) 2006-09-08
WO2006033912A2 (fr) 2006-03-30
EP1799240A2 (fr) 2007-06-27
CA2580281A1 (fr) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2003059291A3 (fr) Traitement des affections osseuses avec des medicaments anabolisants du squelette
WO2005046603A3 (fr) Composes pyridiniques
TW200612892A (en) Novel compounds
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2006015259A3 (fr) Composes et compositions comme modulateurs de recepteurs steroides
WO2010045258A3 (fr) Modulateurs spirocycliques de gpr40
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2002100347A3 (fr) Promedicaments d'analogues de gaba, compositions et utilisations desdits promedicaments
TW200505837A (en) Novel compounds
TW200519075A (en) Novel compounds
WO2007061661A3 (fr) Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
WO2008097428A3 (fr) Composés et compositions tels que des modulateurs d'une activité gpr119
WO2007120689A3 (fr) Procédés d'utilisation du récepteur gpr119 pour identifier des composés utiles pour augmenter la masse osseuse chez un individu
WO2008137787A3 (fr) Thérapie de combinaison avec un composé agissant comme inhibiteur de récepteur à l'adp de plaquettes
WO2007111994A3 (fr) Composés et méthodes pour traitement de troubles associés à un stress du réticulum endoplasmique
JO2800B1 (en) Rosaclubta tetrahydrate compounds [B] indole androgen regulators
WO2007092065A3 (fr) Composés et compositions servant de modulateurs du lxr
TW200630336A (en) Novel compounds
TW200621690A (en) Novel compounds
WO2005105110A3 (fr) Analogues de doxepine et leurs procedes d'utilisation
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
WO2005077122A3 (fr) Composes et compositions convenant comme modulateurs des lxr
WO2006066011A3 (fr) Composes et compositions utilises comme modulateurs de recepteurs steroidiens et d'activites du canal calcium
WO2004030618A3 (fr) Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2580281

Country of ref document: CA

Ref document number: 2005287139

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/003185

Country of ref document: MX

Ref document number: 2007532415

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005287139

Country of ref document: AU

Date of ref document: 20050914

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005287139

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1236/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005797693

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005797693

Country of ref document: EP